EN
HI

MEDICO REMEDIES Share price

MEDICO

HealthcareSmall

50.46

3.50 (-6.49%)
NSE
BSE
Last updated on 9 May, 2025 | 15:51 IST
BUYSELL
Today's High

49.00

Today's Low

52.39

52 Week Low

79.83

52 Week High

79.83

The current prices are delayed, login to your account for live prices

Medico Remedies Chart

MEDICO REMEDIES Share Key Metrics

Volume
2.56 L
Market Cap
418.74 CR
LTQ@LTP
50@50.46
ATP
50.68
Var Margin
10000
Circuit Range
43.16-64.75
Delivery %
34.26
Value
1.30 CR
ASM/GSM
No
Market Lot
1

MEDICO REMEDIES Futures & Options

Data Not Found

MEDICO REMEDIES Corporate Actions

DateAgenda
2025-05-08Audited Results
2025-02-05Quarterly Results
DateEvent TypeAgenda
2025-05-08Board MeetingAudited Results
2025-02-05Board MeetingQuarterly Results

MEDICO REMEDIES News

Buy Medico Remedies for target of Rs 120, says analyst Nikhil Bhatt.

Apr 17 2023 13:10:15
Read More

About MEDICO REMEDIES

NSE : 9667  
BSE : 540937  
ISIN : INE630Y01024  

The Company was incorporated as Medico Remedies Private Limited on March 18 1994 under the Companies Act 1956 with the Registrar of Companies Mumbai bearing  Registration No. 077187. The status of the Company was changed to a public limited company and the name of the Company was changed to Medico Remedies Limited by a  special resolution passed on January 12 2017. A fresh Certificate of Incorporation consequent upon conversion was issued on March 06 2017 by the Registrar of  Companies Mumbai. The Company’s Corporate Identity Number is U24230MH1994PLC077187.The Company Medico Remedies Limited is a pharmaceutical formulation manufacturing company with manufacturing and marketing capabilities in formulation with focus on  anti-infective Beta-Lactums cephalosporins antimalarial antiretroviral anti-ulcer drugs and antacids vitamins haematinics and other supplements. Further in  addition to the above the Company also has manufacturing and marketing capabilities in other drugs such as NSAIDS antihistaminic antidiabetics cardio vascular  drugs diuretics anti-epileptics combination drug kits syrups and cream & gel for various therapeutic segments.The Company began its operations in the year 1994 with manufacturing and servicing of diuretics anti-malarials NSAIDS tablets anti-reterovirals anti-ulcer drugs  and anti-acids tablets. Over the years we have expanded the scale and scope of operations and currently the Company is engaged in manufacture of formulations for  various medicines. As part of this expansion in the year 1999 & 2002 we have acquired two adjacent plots of 1023.50 sq. metres each respectively for setting up the  plant at Palghar Maharashtra. The plant is divided into two units i.e. general formulations unit and betalactam unit; the beta lactam unit is further divided into  two segments –penicillin and cephalosporins.With the long standing operations and quality products we have built a strong relationship with the customers for drug formulations. the clients include Indian as  well as foreign pharmaceutical companies like Anphar Limited Saad Medical Manfes Pharmaceuticals & Chemical Industries Award Global Company Limited Directorate of  Health Services (DHS Maharashtra) to name a few. the Company also earns revenue from the sale of licenses such as FMS license FPS license and MESI license. The  income from sale of such licenses amounts to Rs. 72.47lakhs which is 2.46% of the operational revenue during the period ending September 30 2017.We have an in-house R&D facility and a dedicated QC / QA & microbiology laboratory at the Palghar units to support technology transfer for new products and on-site  process improvement. We have dedicated teams actively involved in R&D and QC / QA Lab activities. the R&D capabilities enable us to support the growth strategy by  developing new products and processes which enhance the product range. The focus of the R&D has been to strive for continuous process improvements and achieving  manufacturing cost efficiencies for existing as well as new formulations. The QC/ QA and microbiology laboratories ensure the quality of raw material dispensed in the  production process and also the finished goods delivered to the customers. This helps in improving the procurement process thus reducing wastages returns and other  related costs.The operational revenue as restated was Rs. 2927.42 lakhs for the period ended September 30 2017 and were Rs. 5441.80 lakhs Rs. 6668.36 lakhs and Rs. 5098.99 lakhs for the Fiscal 2017 2016 and 2015 respectively. the operational revenues increased/ (decreased) by (18.39)% in the fiscal 2017 and 30.78%in the fiscal 2016. the net profit as restated was Rs. 40.02 lakhs for the period ended September 30 2017 and were Rs. 162.81 lakhs Rs. 112.99 lakhs and Rs. 79.20 lakhs in each of the Fiscals 2017 2016 and 2015 respectively. the net profit as restated increased by 40.10% in fiscal 2017 and 42.65 % in the fiscal 2016.MAJOR EVENTS:1994-Incorporated under Companies Act 1956 as Medico Remedies Private Limited1999-Acquired plot at Palghar for setting up manufacturing set-up for general formulations2002-Acquired plot at Palghar for setting up manufacturing set-up for beta lactam2016-Renwed WHO-GMP Certification for the manufacturing facility-Purchased corporate premises at “Hubtown Solaris”2017-Renewed ISO-9001:2015 Certification for the manufacturing facility-Converted into a public limited company and the name of the company was changed to Medico Remedies Ltd

MEDICO REMEDIES Management

NamePosition
Mr. Haresh Kapurlal Mehta Chairman & Wholetime Director
Mr. Harshit Haresh Mehta Managing Director
Mr. Rishit Haresh Mehta Whole Time Director
Mr. Dayanand Shivshankar Mathapati Additional Executive Director
Mrs. Rita Haresh Mehta Woman Non Executive Director
Read More

MEDICO REMEDIES FAQs

The Buying Price of MEDICO REMEDIES share is 0 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy MEDICO REMEDIES share to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of MEDICO REMEDIES shares is 41.37. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio MEDICO REMEDIES shares is 6.68. Useful to assess the stock's value relative to its book value.

To assess MEDICO REMEDIES’s valuation compare Sector P/E, P/B which are 37.32 & 4.64 with sector averages, along with growth rates and financial metrics.

The Market Cap of MEDICO REMEDIES is 418.74 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of MEDICO REMEDIES share price is 79.83 & 34.80. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.